IWM
ADCT icon

IHT Wealth Management’s ADC Therapeutics ADCT Stock Holding History

IHT Wealth Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,110
Closed -$29.5K – 970
2023
Q1 		$29.5K Hold
15,110
– – ﹤0.01% 935
2022
Q4 		$58K Buy
+15,110
New +$60.4K ﹤0.01% 881

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

IHT Wealth Management's ADCT Position: Q2 2023 in Review

IHT Wealth Management sold out of ADC Therapeutics (ADCT) in Q2 2023, closing a stake of 15,110 shares — an estimated $29.5K sold.

IHT Wealth Management first reported a position in ADCT in Q4 2022 and held it in 2 quarters. The position peaked at $58K in Q4 2022. 56 funds tracked by Wall St. Rank hold ADCT as of Q2 2023.

  • IHT Wealth Management reported no remaining ADC Therapeutics position as of Q2 2023 after selling out during the quarter.
  • IHT Wealth Management sold 15,110 ADC Therapeutics shares in Q2 2023, an estimated $29.5K.
  • IHT Wealth Management first reported a position in ADC Therapeutics in Q4 2022 and held it in 2 quarters.
  • IHT Wealth Management's ADC Therapeutics position peaked at $58K in Q4 2022.
  • 56 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2023.

Based on IHT Wealth Management's 13F filing for Q2 2023, filed 15 Aug 2023.